Financial Tear Sheet

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development and commercialization of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In March 2017, the company completed enrollment in the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. In December 2016, the company initiated the FAB-C exploratory Phase 2 clinical trial in patients with Fragile X syndrome.

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in clinical development. A Phase 1 clinical trial was initiated in the first half of 2017, and the initiation of Phase 2 clinical programs is expected in the second half of 2017.

As of December 31, 2016, cash and cash equivalents totaled $31.0 million. In the first quarter of 2017, the Company completed a follow-on offering resulting in net proceeds of $54.3 million. The Company believes that the cash at year-end 2016 and the net proceeds from the Q1 2017 raise should be sufficient to develop five Phase 3 ready programs and, assuming feedback from the FDA supports a decision to move forward, initiate at least one Phase 3 program and fund operations and capital requirements into 2019.

Zynerba Investor Contact
Jim Fickenscher, CFO and VP Corporate Development
484.581.7483
Argot Partners Investor Contact
Kimberly Minarovich 212.600.1902

Stock Performance

ZYNE (COMMON STOCK)	
Exchange	NASDAQ (US Dollar)
Price	$6.25
Change (%)	▼ 0.07 (1.11%)
Volume	424,137
52 Week Low	$5.42
Market Cap	$82,857,994
Rolling EPS	-2.62
PE Ratio	0
Shares Outstanding	13,257,279

Data as of 08/18/17 4:00 p.m. ET

Recent Headlines & Events

08.14.17 - 6:45 a.m.
Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthritis

08.07.17 - 6:45 a.m.
Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures

There are currently no events scheduled.

Clinical Pipeline & Expected Upcoming Milestones



SEC Filings

FILING DATE	FORM
08/14/17	8-K
08/07/17	8-K
08/01/17	10-Q
08/01/17	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources